hemophilia
Conditions
Interventions
Group A:Microinvasive surgery
Group B:Microinvasive surgery
Sponsors
Shanghai Public Health Clinical Center
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: The hemophilia A patients enrolled in the study received small doses of clotting factor prophylaxis according to individual clotting factor activity during the experiment, using long-course recombinant human clotting factor (trade name: Baikoqi, Bayer Pharmaceuticals, Germany) VIII 5-15U/Kg/times, iv 2 times/week, treatment for 1 year. HIV-positive patients receive HAART treatment. All patients underwent personalized traction rehabilitation for 1 year, and rehabilitation was suspended if there were special conditions such as adjustment medication or joint bleeding. 1. Measure the body temperature, perform the VAS score, and check the infrared heat map. Combined with the blood test results, determine whether to add clotting factors and maintain the clotting factor activity >1%; 2. To identify the diagnosis of bone pseudotumor in HIV-positive hemophilia A patients, to diagnose the pseudotumor by musculoskeletal ultrasound, CT or MRI, and to guide the percutaneous balloon dilation in the C-arm fluoroscopy. Invasive surgery patients; 3. the patient himself and his family agree to surgery.
Exclusion criteria
Exclusion criteria: 1. Knee joint fusion; 2. knee joint fracture; 3. severe skin infections, defects; 4. patients with malignant tumors; 5. the patient himself with mental and neurological diseases, persistent or intermittent seizures, incomplete behavior; 6. the patient and his family do not receive surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS score;ODI score; | — |
Secondary
| Measure | Time frame |
|---|---|
| APTT;FVIII activity;Saliva and hair cortisol levels; | — |
Contacts
Public ContactLU MING
Shanghai Public Health Clinical Center
Outcome results
None listed